sorafenib has been researched along with Cancer of Prostate in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (22.22) | 29.6817 |
| 2010's | 28 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abou El Ella, DA; Abou-Seri, SM; Ali, MM; Eldehna, WM | 1 |
| Jackson, R; Johnson, PJ; Psarelli, E | 1 |
| Chen, N; Chen, X; Li, X; Pan, X; Su, Z; Tan, J; Xu, M; Xu, Y; Zhang, M; Zhou, Q | 1 |
| Che, X; Chen, F; Chen, X; Fan, B; Song, X; Wang, J; Wang, X; Yang, D; Zhang, Z | 1 |
| Waxman, DJ; Zhang, K | 1 |
| Bruns, CJ; Clevert, DA; Cyran, CC; Dietrich, O; Hinkel, R; Nikolaou, K; Paprottka, PM; Reiser, MF; Schwarz, B; Sourbron, S; von Einem, JC; Wintersperger, BJ | 1 |
| Du, G; Tian, J; Wang, H; Ye, L; Yu, P; Zhang, J | 1 |
| Bernardini, M; Brossa, A; Bussolati, B; Fiorio Pla, A; Genova, T; Gkika, D; Grolez, G; Leroy, X; Prevarskaya, N; Villers, A | 1 |
| Du, G; Tian, J; Wang, H; Ye, L; Yu, P; Zhang, J; Zuo, Y | 1 |
| De Velasco, MA; Hatanaka, Y; Kura, Y; Minami, T; Nishio, K; Nozawa, M; Oki, T; Ozeki, T; Shimizu, N; Uemura, H; Yamamoto, Y; Yoshikawa, K; Yoshimura, K | 1 |
| Baltatzis, G; Björklund, AC; Chioureas, D; Egevad, L; Fonseca, P; Gogvadze, V; Grandér, D; Kharaziha, P; Lennartsson, L; Nilsson, S; Panaretakis, T; Rodriguez, P; Zhivotovsky, B | 1 |
| Dolcet, X; Dosil, MA; Eritja, N; Felip, I; Gatius, S; Matias-Guiu, X; Mirantes, C; Santacana, M | 1 |
| Arora, JS; Ashe, S; Halliburton, G; He, J; John, VT; Khismatullin, DB; Murad, HY; Yu, H | 1 |
| Checcaglini, F; Colloca, G; Venturino, A | 1 |
| Aragon-Ching, JB; Arlen, PM; Chen, CC; Dahut, WL; Draper, D; Figg, WD; Gulley, JL; Jain, L; Jones, E; Steinberg, SM; Venitz, J; Wright, JJ | 1 |
| Aragon-Ching, JB; Dahut, WL | 2 |
| Chen, N; Chen, XQ; Huang, R; Huang, Y; Zeng, H | 1 |
| Farnebo, M; Grandér, D; Kharaziha, P; Lennartsson, L; Mahmoudi, S; Nilsson, S; Panaretakis, T; Thyrell, L; Ullén, A | 1 |
| Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F | 1 |
| Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
| Beardsley, EK; Chi, KN; Ellard, SL; Hotte, SJ; Kollmannsberger, C; Mukherjee, SD; North, S; Winquist, E | 1 |
| Bruns, CJ; Clevert, DA; Cyran, CC; Dietrich, O; Eschbach, R; Hinkel, R; Ingrisch, M; Nikolaou, K; Paprottka, PM; Reiser, MF; Schwarz, B; von Einem, JC; Wintersperger, BJ | 1 |
| Dai, X; He, F; Lian, J; Ni, Z; Smith, AR; Su, C; Xu, L | 1 |
| Bruns, CJ; Cyran, CC; Dietrich, O; Hinkel, R; Ingrisch, M; Nikolaou, K; Paprottka, PM; Pietsch, H; Reiser, MF; Schwarz, B; Sourbron, S; von Einem, J; Wintersperger, BJ | 1 |
| Augsten, M; Björklund, AC; Egevad, L; Grander, D; Kharaziha, P; Kroemer, G; Li, Q; Nilsson, S; Panaretakis, T; Rodriguez, P; Rundqvist, H; Ullén, A; Wiklund, P | 1 |
| Dahut, W; English, BC; Federspiel, J; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kim, A; Kirkland, CT; Kohn, E; Kummar, S; Peer, CJ; Richardson, ED; Sissung, TM; Troutman, SM; Venzon, D; Widemann, B; Woo, S; Yarchoan, R | 1 |
| Culig, Z; Erb, HH; Hobisch, A; Oh, SJ; Santer, FR | 1 |
| Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S | 1 |
| Beumer, JH; Bitran, JD; Christner, SM; Egorin, MJ; Lestingi, TM; Nabhan, C; Tolzien, K; Valdez, TV; Villines, D | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Azad, NS; Cowen, EW; Dahut, W; Gutierrez, M; Kong, HH; Turner, ML | 1 |
| Tan, W | 1 |
| Burkholder, I; Dittrich, C; Edler, L; Frost, A; Gillessen, S; Hanauske, AR; Hochhaus, A; Morant, R; Mross, K; Scheulen, M; Steinbild, S; Strumberg, D | 1 |
| Chi, KN; Czaykowski, P; Ellard, SL; Gauthier, I; Hansen, C; Hotte, SJ; Moore, M; Ruether, JD; Schell, AJ; Seymour, L; Taylor, S; Walsh, W | 1 |
| Aragon-Ching, JB; Arlen, PM; Cao, L; Chen, CC; Dahut, WL; Figg, WD; Gulley, JL; Jain, L; Jones, E; Posadas, E; Scripture, C; Steinberg, SM; Venitz, J; Wright, JJ; Yu, Y | 1 |
4 review(s) available for sorafenib and Cancer of Prostate
| Article | Year |
|---|---|
VEGF inhibitors and prostate cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Humans; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Quinazolines; Signal Transduction; Sorafenib; Thalidomide; Vascular Endothelial Growth Factors | 2009 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
[Promising new treatment options for metastatic androgen-independent prostate cancer].
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides | 2007 |
7 trial(s) available for sorafenib and Cancer of Prostate
| Article | Year |
|---|---|
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Disease-Free Survival; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Orchiectomy; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; raf Kinases; Soft Tissue Neoplasms; Sorafenib; Treatment Outcome | 2009 |
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Nitriles; Orchiectomy; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib; Time Factors; Tosyl Compounds; Treatment Failure | 2012 |
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Niacinamide; Orchiectomy; Phenylurea Compounds; Pilot Projects; Prednisone; Prospective Studies; Prostatic Neoplasms; Pyridines; Sorafenib; Taxoids; Testosterone | 2012 |
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Castration; Drug Administration Schedule; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Retreatment; Sorafenib; Treatment Failure | 2012 |
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Fatigue; Humans; Male; Middle Aged; Nausea; Niacinamide; Pain; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2007 |
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; Biomarkers, Tumor; Canada; Cell Proliferation; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2008 |
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2008 |
25 other study(ies) available for sorafenib and Cancer of Prostate
| Article | Year |
|---|---|
1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.
Topics: Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Male; Molecular Docking Simulation; Phthalazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Reply to N. Personeni et al.
Topics: Carcinoma, Hepatocellular; Hepacivirus; Humans; Liver Neoplasms; Prostatic Neoplasms; Sorafenib | 2017 |
MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components.
Topics: Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Humans; Male; MAP Kinase Signaling System; MicroRNAs; Mitogen-Activated Protein Kinase 1; Neoplasm Invasiveness; Prostatic Neoplasms; Ribosomal Protein S6 Kinases, 90-kDa; Serum Response Factor; Sorafenib | 2018 |
Zinc sensitizes prostate cancer cells to sorafenib and regulates the expression of Livin.
Topics: Actins; Adaptor Proteins, Signal Transducing; Apoptosis; Cell Line, Tumor; Cell Survival; Cytoskeleton; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Male; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Sorafenib; Zinc Sulfate | 2013 |
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Disease Models, Animal; Humans; Hypoxia; Imidazoles; Indazoles; Male; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Contrast Media; Image Enhancement; Immunohistochemistry; Magnetic Resonance Imaging; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Rats; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Burden | 2013 |
NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; HCT116 Cells; Hep G2 Cells; HT29 Cells; Humans; Male; MAP Kinase Kinase Kinases; MCF-7 Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2015 |
Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Indoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Discovery; Enzyme Activation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Quinazolines; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2014 |
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Disease Models, Animal; Everolimus; Genetic Engineering; Homozygote; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Knockout; Neoplasms, Experimental; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Sorafenib | 2015 |
Sorafenib-induced defective autophagy promotes cell death by necroptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Blotting, Western; Cells, Cultured; Drug Resistance, Neoplasm; Embryo, Mammalian; Fibroblasts; Flow Cytometry; Humans; Immunoenzyme Techniques; Immunoprecipitation; Male; Mice; Mice, Knockout; Microtubule-Associated Proteins; Necrosis; Niacinamide; Phagosomes; Phenylurea Compounds; Prostatic Neoplasms; Receptor-Interacting Protein Serine-Threonine Kinases; RNA-Binding Proteins; Sorafenib; Tissue Array Analysis | 2015 |
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neoplasms; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Sorafenib; Thyroid Neoplasms | 2016 |
Ablative Focused Ultrasound Synergistically Enhances Thermally Triggered Chemotherapy for Prostate Cancer in Vitro.
Topics: Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cryoelectron Microscopy; Drug Delivery Systems; High-Intensity Focused Ultrasound Ablation; Humans; Liposomes; Male; Microscopy, Confocal; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Sorafenib | 2016 |
About sorafenib in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Male; Niacinamide; Orchiectomy; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib | 2008 |
About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Humans; Indoles; Male; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.
Topics: Apoptosis; Benzenesulfonates; Caspase 3; Caspases; Cell Line, Tumor; Cytochromes c; Extracellular Signal-Regulated MAP Kinases; Humans; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Survivin | 2010 |
Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Carcinoma; Drug Evaluation, Preclinical; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Male; Niacinamide; Phagosomes; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Pyridines; Sorafenib; Transfection; Tumor Cells, Cultured | 2010 |
Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Drug Screening Assays, Antitumor; Endothelium, Vascular; Fluorescent Antibody Technique, Direct; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Pericytes; Phenylurea Compounds; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Cell Line, Tumor; Contrast Media; Iohexol; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Rats; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Statistics as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
Topics: Androgens; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-2 Homologous Antagonist-Killer Protein; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Gossypol; Humans; Male; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Time Factors; Xenograft Model Antitumor Assays | 2012 |
Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Contrast Media; Humans; Image Interpretation, Computer-Assisted; Immunoenzyme Techniques; Magnetic Resonance Imaging; Male; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Random Allocation; Rats; Sorafenib | 2012 |
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Primary Cell Culture; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins pp60(c-src); Pyridines; Signal Transduction; Sorafenib | 2012 |
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Bilirubin; Clinical Trials as Topic; Disease-Free Survival; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Pilot Projects; Polymorphism, Genetic; Prostatic Neoplasms; Pyridines; Sorafenib; UDP-Glucuronosyltransferase 1A9 | 2012 |
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 2; Down-Regulation; Humans; Male; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Sorafenib | 2012 |
Keratoacanthomas associated with sorafenib therapy.
Topics: Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Facial Dermatoses; Female; Humans; Keratoacanthoma; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neck; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Sorafenib | 2007 |